Medication Guide App

Study Identifies Novel Glycan Markers, Anti-L & Anti-C, That Predict Aggressive Crohn's Disease and Improve Differentiation Between Crohn's Disease and Ulcerative Colitis

SAN DIEGO--(BUSINESS WIRE)--May 19, 2008 - DDW(R), Dr. Cynthia Seow, an IBD Research Fellow at Mount Sinai Hospital at the University of Toronto, will present today results of a major study led by Dr. Mark Silverberg that successfully demonstrated a panel of serological markers, in particular Glycominds' IBDX(R) panel of biomarkers plus two new glycan markers anti-Chitin (anti-C) and anti-Laminarin (anti-L), improve differentiation between Crohn's Disease and Ulcerative Colitis and independently predicts patients with aggressive Crohn's Disease.

A blinded study on 818 pediatric and adult Inflammatory Bowel Disease (IBD) patients were analyzed with Glycominds' current IBDX(R) panel (ACCA, ALCA, AMCA & gASCA), in addition to pANCA and Glycominds' anti-C and anti-L markers. Patients were characterized using the Montreal classification. Anti-C is significantly associated with a penetrating phenotype and with perianal disease. Anti-L is significantly improved differentiation between Crohn's Disease and Ulcerative Colitis and within Crohn's disease is significantly associated with early disease onset, more aggressive penetrating phenotype and the need for abdominal surgery.

"The validation of two new markers to both improve diagnosis of IBD and to identify patients who will have more aggressive Crohn's disease is an important advance. These markers will give physicians new tools to improve treatment of patients," said Dr. Silverberg. "This study is one of the largest studies performed showing the clinical utility of using serologic markers."

These two new anti-glycan serological markers will be added to Glycominds' IBDX(R) panel over the next year. Glycominds' IBDX(R) test is currently offered in Israel and Europe. The IBDX(R) test will be available in the United States in 2008 in conjunction with a laboratory partner, according to Steven Lehrer, President of Glycominds Inc. "Anti-C and anti-L markers will be part of Glycominds' efforts to continually offer the most comprehensive Inflammatory Bowel Disease serologic tests enabling physicians to identify which patients will develop more complicated and aggressive disease to improve patient care," according to Mr. Lehrer.

About Glycominds

Glycominds Inc. is Glycominds, Ltd. US Subsidiary. Glycominds is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds products include IBDX(R), a blood test for early diagnosis of Inflammatory IBD and the prognosis of Crohn's disease severity; gMS(R) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(R) PRO, a prognostic test for MS activity. Glycominds' other pipeline products include blood tests for the prediction of recurrent pregnancy loss and first-in-class screening tests for breast and colorectal cancers.

www.glycominds.com

Contact

Glycominds Ltd.
Michal Gruengard, +972-8918-1080
IBDX® product manager
contactus@glycominds.com

Posted: May 2008

View comments

Hide
(web1)